317 related articles for article (PubMed ID: 29131038)
1. Bullous Diseases.
Corbaux C; Joly P
Curr Probl Dermatol; 2018; 53():64-69. PubMed ID: 29131038
[TBL] [Abstract][Full Text] [Related]
2. Biologics in autoimmune bullous diseases: Current scenario.
Bishnoi A; De D; Handa S; Mahajan R
Indian J Dermatol Venereol Leprol; 2021; 87(5):611-620. PubMed ID: 34245525
[TBL] [Abstract][Full Text] [Related]
3. Bullous autoimmune dermatoses.
Hofmann SC; Juratli HA; Eming R
J Dtsch Dermatol Ges; 2018 Nov; 16(11):1339-1358. PubMed ID: 30395395
[TBL] [Abstract][Full Text] [Related]
4. A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy.
Kianfar N; Dasdar S; Daneshpazhooh M; Aryanian Z; Goodarzi A
Exp Dermatol; 2023 Jul; 32(7):934-944. PubMed ID: 37150538
[TBL] [Abstract][Full Text] [Related]
5. Current treatment of autoimmune blistering diseases.
Kasperkiewicz M; Schmidt E
Curr Drug Discov Technol; 2009 Dec; 6(4):270-80. PubMed ID: 20025595
[TBL] [Abstract][Full Text] [Related]
6. [Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases].
Kasperkiewicz M; Zillikens D
Hautarzt; 2007 Feb; 58(2):115-6, 118-21. PubMed ID: 17237928
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune blistering diseases: promising agents in clinical trials.
Olbrich H; Sadik CD; Schmidt E
Expert Opin Investig Drugs; 2023; 32(7):615-623. PubMed ID: 37526503
[TBL] [Abstract][Full Text] [Related]
8. Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature.
Kremer N; Snast I; Cohen ES; Hodak E; Mimouni D; Lapidoth M; Mazor S; Levi A
Am J Clin Dermatol; 2019 Apr; 20(2):209-216. PubMed ID: 30421306
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update.
Czernik A; Toosi S; Bystryn JC; Grando SA
Autoimmunity; 2012 Feb; 45(1):111-8. PubMed ID: 21923613
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in refractory autoimmune bullous diseases.
Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil for the management of autoimmune bullous diseases.
Eskin-Schwartz M; David M; Mimouni D
Dermatol Clin; 2011 Oct; 29(4):555-9. PubMed ID: 21924997
[TBL] [Abstract][Full Text] [Related]
12. Rituximab and its use in autoimmune bullous disorders.
Daniel BS; Murrell DF; Joly P
Dermatol Clin; 2011 Oct; 29(4):571-5. PubMed ID: 21925000
[TBL] [Abstract][Full Text] [Related]
13. Retrospective Study on Autoimmune Blistering Disease in Paediatric Patients.
Kong YL; Lim YL; Chandran NS
Pediatr Dermatol; 2015; 32(6):845-52. PubMed ID: 26391853
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapies for Autoimmune Bullous Diseases: Current Status.
Amber KT; Maglie R; Solimani F; Eming R; Hertl M
Drugs; 2018 Oct; 78(15):1527-1548. PubMed ID: 30238396
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in treatment-resistant autoimmune blistering skin disorders.
Schmidt E; Bröcker EB; Goebeler M
Clin Rev Allergy Immunol; 2008 Feb; 34(1):56-64. PubMed ID: 18270859
[TBL] [Abstract][Full Text] [Related]
16. Practice and Educational Gaps in Blistering Disease.
Ehsani-Chimeh N; Marinkovich MP
Dermatol Clin; 2016 Jul; 34(3):251-6. PubMed ID: 27363880
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients.
Liu X; Ma J; Qiu X; Hong D; Wang L; Shi Z
Eur J Dermatol; 2021 Dec; 31(6):846-847. PubMed ID: 35107075
[No Abstract] [Full Text] [Related]
18. Biological treatment for bullous pemphigoid.
Oren-Shabtai M; Mimouni D; Nosrati A; Atzmony L; Kaplan B; Barzilai A; Baum S
Front Immunol; 2023; 14():1157250. PubMed ID: 37180101
[TBL] [Abstract][Full Text] [Related]
19. IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid.
James T; Salman S; Stevenson B; Bundell C; Kelly G; Nolan D; John M
Clin Immunol; 2019 Jan; 198():54-56. PubMed ID: 30557620
[TBL] [Abstract][Full Text] [Related]
20. Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.
Cao P; Xu W; Zhang L
Front Immunol; 2022; 13():928621. PubMed ID: 35769474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
